It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
After initiating antiretroviral therapy (ART), a rapid decline in HIV viral load is followed by a long period of undetectable viremia. Viral outgrowth assay suggests the reservoir continues to decline slowly. Here, we use full-length sequencing to longitudinally study the proviral landscape of four subjects on ART to investigate the selective pressures influencing the dynamics of the treatment-resistant HIV reservoir. We find intact and defective proviruses that contain genetic elements favoring efficient protein expression decrease over time. Moreover, proviruses that lack these genetic elements, yet contain strong donor splice sequences, increase relatively to other defective proviruses, especially among clones. Our work suggests that HIV expression occurs to a significant extent during ART and results in HIV clearance, but this is obscured by the expansion of proviral clones. Paradoxically, clonal expansion may also be enhanced by HIV expression that leads to splicing between HIV donor splice sites and downstream human exons.
How HIV reservoirs are shaped over time on antiviral therapy is poorly understood. Here, the authors analyze the dynamics of the HIV reservoir by longitudinal proviral sequencing revealing that HIV reservoir expression can contribute to its clearance and paradoxically even to its persistence.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 University of Pennsylvania, Department of Pathology and Laboratory Medicine, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972)
2 University of Pennsylvania, Department of Pathology and Laboratory Medicine, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); Northwestern University, Department of Molecular Biosciences, Evanston, USA (GRID:grid.16753.36) (ISNI:0000 0001 2299 3507)
3 University of Pennsylvania, Department of Pathology and Laboratory Medicine, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); University of Messina, Department of Clinical and Experimental Medicine, Unit of Infectious Diseases, Messina, Italy (GRID:grid.10438.3e) (ISNI:0000 0001 2178 8421)
4 National Institutes of Health, Laboratory of Immunoregulation, National Institutes of Allergy & Infectious Diseases, Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165)
5 Weill Cornell Medical College, Infectious Disease Division, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X)
6 University of North Carolina at Chapel Hill, Department of Microbiology and Immunology, Chapel Hill, USA (GRID:grid.10698.36) (ISNI:0000000122483208)
7 University of Amsterdam, Laboratory of Experimental Virology, Department of Medical Microbiology, Academic Medical Center, Amsterdam, The Netherlands (GRID:grid.7177.6) (ISNI:0000000084992262)
8 University of Pennsylvania, Department of Biostatistics, Epidemiology and Informatics, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972)
9 Leidos Biomedical Research Inc., supporting the Division of Clinical Research, NIAID, Laboratory of Human Retrovirology and Immunoinformatics, Frederick National Laboratories for Cancer Research, Frederick, USA (GRID:grid.25879.31)
10 University of Messina, Department of Clinical and Experimental Medicine, Unit of Infectious Diseases, Messina, Italy (GRID:grid.10438.3e) (ISNI:0000 0001 2178 8421)